The synthetic endoperoxide project was the very first discovery project taken into MMV’s portfolio back in 2000. Today, OZ439, one of the key molecules to emerge, and one of the next generation antimalarials, is on track to potentially replace artemisinin and become a part of the much-needed one-dose cure for malaria.
The success of this project can be attributed to the commitment, enthusiasm and range of scientific expertise of its partners from across the globe. Chemistry expertise was provided by the Nebraska (USA) and Monash (Australia) teams who synthesized the target compounds and explored how the human body reacts to the drug, SwissTPH (Switzerland) evaluated the antimalarial potential of the molecules. MMV has led the coordination of the project, and is leading the clinical development.